title: Can We Better Optimize Vancomycin Monotherapy?
authors.affiliation: Department of Medicine, Baylor College of Medicine, Department of Medicine.
authors.forename: Sapna A
authors.initials: SA
authors.lastname: Mehta
authors.affiliation: Department of Pharmacy, Baylor-St. Luke's Medical Center, Houston, Texas.
authors.forename: Hannah R
authors.initials: HR
authors.lastname: Russo
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000453:epidemiology*; D014640:Vancomycin / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin; D014640:Vancomycin